Sio Capital Management LLC Purchases New Stake in Senseonics Holdings, Inc. $SENS

Sio Capital Management LLC acquired 4,852,298 shares of Senseonics Holdings, Inc. in Q2, valued at $2,312,000, making it 0.9% of their holdings. Other hedge funds also adjusted their positions in Senseonics. Insider purchases were made by CFO Frederick T. Sullivan and Director Edelman Steven. Analysts have given the stock a consensus 'Buy' rating with a target price of $22.70. Senseonics focuses on continuous glucose monitoring systems for diabetes.

Sio Capital Management LLC purchased a new stake in shares of Senseonics Holdings, Inc. (NYSE:SENS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 4,852,298 shares of the company's stock, valued at approximately $2,312,000. Senseonics accounts for approximately 0.9% of Sio Capital Management LLC's holdings, making the stock its 29th largest holding. Sio Capital Management LLC owned about 0.74% of Senseonics at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of SENS. Elite Life Management LLC bought a new position in shares of Senseonics during the second quarter valued at about $36,000. Charles Schwab Investment Management Inc. grew its stake in shares of Senseonics by 4.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,502,326 shares of the company's stock worth $2,298,000 after purchasing an additional 162,628 shares during the last quarter. Informed Momentum Co LLC purchased a new position in Senseonics during the 1st quarter valued at about $559,000. Keynote Financial Services LLC raised its position in Senseonics by 1,120.2% during the 2nd quarter. Keynote Financial Services LLC now owns 208,285 shares of the company's stock valued at $99,000 after purchasing an additional 191,215 shares during the last quarter. Finally, State of Wyoming bought a new position in Senseonics during the 1st quarter valued at approximately $40,000. Hedge funds and other institutional investors own 12.36% of the company's stock.

Insider Activity

In other Senseonics news, CFO Frederick T. Sullivan purchased 5,415 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was bought at an average cost of $5.88 per share, with a total value of $31,840.20. Following the transaction, the chief financial officer directly owned 157,028 shares in the company, valued at approximately $923,324.64. The trade was a 3.57% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Edelman Steven acquired 10,000 shares of the company's stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average cost of $6.55 per share, for a total transaction of $65,500.00. Following the purchase, the director directly owned 74,708 shares of the company's stock, valued at $489,337.40. This represents a 15.45% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 30,415 shares of company stock worth $184,790. Corporate insiders own 3.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus initiated coverage on Senseonics in a research report on Tuesday, October 21st. They issued a "hold" rating and a $9.00 price objective on the stock. TD Cowen dropped their price target on Senseonics from $25.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, November 5th. HC Wainwright boosted their price objective on shares of Senseonics to $18.50 and gave the company a "buy" rating in a research report on Thursday, November 6th. Finally, Barclays restated an "overweight" rating and issued a $31.00 price objective (up from $1.50) on shares of Senseonics in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $22.70.

View Our Latest Stock Analysis on SENS

Senseonics Trading Down 2.6%

NYSE SENS opened at $6.02 on Tuesday. The firm has a market capitalization of $245.97 million, a PE ratio of -46.31 and a beta of 0.79. The stock's 50 day moving average is $7.45 and its 200 day moving average is $9.05. Senseonics Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $28.00. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Senseonics Profile

(Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Should You Invest $1,000 in Senseonics Right Now?

Before you consider Senseonics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senseonics wasn't on the list.

While Senseonics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here